APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)

Launched by WAKE FOREST UNIVERSITY HEALTH SCIENCES · Jul 30, 2018

Keywords

ClinConnect Summary

The APOLLO study is a clinical trial aimed at improving the outcomes of kidney transplants and ensuring the safety of living kidney donations. It focuses on a specific gene called apolipoprotein L1 (APOL1), which can affect kidney health. This gene is more common among individuals of African ancestry, and certain variations can increase the risk of kidney disease. By testing the DNA of both kidney donors and recipients for APOL1 variations, researchers hope to understand how these genetic factors might influence the success of kidney transplants.

To participate in this study, living kidney donors must have African ancestry, which includes groups such as African Americans, Afro-Caribbeans, Hispanic Blacks, or Africans. It's important for potential donors to be willing to provide informed consent to participate. While enrollment for kidney transplant recipients has ended, the trial will continue to recruit living donors for the next two years. Participants can expect to contribute a DNA sample and be part of a study that may help improve kidney transplant outcomes for future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria for Living Donors:
• • Living kidney donors with self-reported recent African ancestry (defined as African American, Afro-Caribbean, Hispanic black or African) will be eligible for inclusion.
• Exclusion Criteria for Living Donors:
• • Participants who are unable or unwilling to provide informed consent.
• • Enrollment and bio sample collection from deceased donors at OPOs ended on May 31, 2023 and recruiting kidney transplant recipients ended on June 15, 2023.
• • Phase II started on 9/1/2023 and only Living Donors will be recruited for an additional 2 years.